European Bladder Cancer Therapeutics MarketsFrost & SullivanAugust 14, 2007 94 Pages - SKU: MC1551132 |
|
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
5/11/2012 | published by: Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a
|
more...
|
$3,995.00
|
|
Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
5/21/2012 | published by: GlobalData
Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, “Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report
|
more...
|
$3,995.00
|
|
Czech Republic Nephrology and Urology Devices Market Outlook to 2018 - Incontinence Devices, Renal Dialysis Equipment and Lithotripters
5/8/2012 | published by: GlobalData
Czech Republic Nephrology and Urology Devices Market Outlook to 2018 - Incontinence Devices, Renal Dialysis Equipment and Lithotripters Summary GlobalData’s new report, “Czech Republic Nephrology and Urology Devices Market Outlook to 2018 - Incontinence Devices, Renal Dialysis
|
more...
|
$2,500.00
|
|
World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments)
3/1/2012 | published by: Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological drugs, describing the global market and identifying major market factors
|
more...
|
$3,995.00
|
|
Triple Analysis: Breast Cancer, Lymphoma and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lymphoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Melanoma and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Pancreatic Cancer and Protein Kinase Inhibitors
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Peptides
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Each of these three individual parts is
|
more...
|
$5,175.00
|
Related Markets
Oncology/Hematology Reports
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Peptides
- Triple Analysis: Prostate Cancer, Protein Kinase Inhibitors and Antibodies
- Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors
- Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors
